Get started

Financials · PAVM

PAVmed Inc. (PAVM) financials

For the twelve months ended Jun 30, 2026, PAVmed Inc. reported $112.0K of revenue and -$12.09M of net income.

Revenue, TTM
$112.0K
Revenue growth, YoY
-89.0%
Net income, TTM
-$12.09M
Net margin
-10794.6%
Free cash flow, TTM
-$7.78M
Cash
$3.78M
P/S
116.37
Market cap
$13.0M
Annual revenue$71.0K
FY2021FY2025
Annual net income$401.0K
FY2016FY2025
Annual free cash flow-$5.24M
FY2016FY2025

PAVM revenue and earnings growth

PAVM revenueQ2 2026$33.0K

Quarter YoY
+450.0%
QoQ
+50.0%
FY YoY
-97.6%

PAVM revenue was $33.0K in fiscal Q2 2026 (ended Jun 30, 2026), up 450.0% from a year earlier and up 50.0% from the prior quarter. For the full fiscal 2025 it was $71.0K, down 97.6% from fiscal 2024. It rose in 2 of the last 4 fiscal years.

PAVM net incomeQ2 2026-$5.38M

FY YoY
-99.0%

PAVM net income was -$5.38M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$11.92M a year earlier. For the full fiscal 2025 it was $401.0K, down 99.0% from fiscal 2024.

PAVM EPSQ2 2026-$0.87

PAVM diluted EPS was -$0.87 in fiscal Q2 2026 (ended Jun 30, 2026). For the full fiscal 2025 it was -$5.63.

PAVM free cash flowQ2 2026-$2.68M

PAVM free cash flow was -$2.68M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$1.19M a year earlier. For the full fiscal 2025 it was -$5.24M, compared with -$33.61M in fiscal 2024.

Export CSV

Income statement

Income statement
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Revenue$71.0K$3.00M$2.45M$377.0K$500.0K-----
Cost of revenue$218.0K$4.84M$6.42M$3.61M$585.0K-----
Gross profit-$147.0K-$1.84M-$3.97M-$3.24M-$85.0K-----
Research and development$4.49M$5.93M$14.28M$25.34M$19.85M$10.96M$6.63M$4.25M$2.62M$1.72M
Selling, general and admin$16.25M$24.52M$30.95M$41.41M$25.42M$9.60M$7.67M$6.31M$5.41M$3.93M
Operating income-$21.81M-$44.49M-$68.80M-$91.09M-$54.39M-$23.35M-$14.29M-$10.56M-$8.03M-$5.65M
Interest expense$21.0K$45.0K-----$2.39M$724.7K-
Pre-tax income-$2.47M$28.43M-$79.26M-$103.24M-$56.13M-$35.89M-$17.27M-$18.17M-$9.52M-$5.65M
Income tax$0$0--------
Net income$401.0K$39.79M-$64.17M-$88.98M-$50.35M-$34.28M-$16.46M-$17.97M-$9.52M-$5.65M
EPS, basic-$5.63$99.15-$274.80-$6763.50-$292.50-$324.00-$243.00-$364.50-$319.50-$198.00
EPS, diluted-$5.63$14.90-$274.80-$6763.50-$292.50-$324.00-$243.00-$364.50-$319.50-$198.00
Diluted shares670,4662.2M241,051.53313,196.458172,257.26105,404.767,105.46249,502.99329,991.00228,827.007

Balance sheet

Balance sheet
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Cash and equivalents$1.54M$1.19M$19.64M$39.74M$77.26M$17.26M$6.22M$8.22M$1.54M$585.7K
Receivables$15.0K$18.0K$61.0K$17.0K$200.0K-----
Inventory--$278.0K$111.0K------
Current assets$2.56M$2.16M$24.50M$43.93M$82.64M$18.94M$6.55M$8.46M$1.62M$741.2K
Total assets$38.81M$30.66M$33.12M$53.98M$86.98M$19.78M$7.24M$8.50M$1.64M$870.4K
Current liabilities$14.84M$35.45M$54.18M$41.20M$7.56M-$11.88M$10.97M$2.54M$1.19M
Total liabilities$16.51M$37.69M$57.14M$43.05M$7.56M$20.25M$11.88M$10.97M$4.49M$1.19M
Shareholders' equity$33.97M-$7.03M-$24.02M$10.93M$79.42M-$473.0K-$4.64M-$2.48M-$2.85M-$319.1K

Cash flow

Cash flow
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Operating cash flow-$5.21M-$33.55M-$52.04M-$70.98M-$40.59M-$21.91M-$13.36M-$8.79M-$6.61M-$4.45M
Capital expenditures$31.0K$55.0K$242.0K$1.54M$1.47M$55.0K$27.0K$26.6K$5.3K$21.8K
Free cash flow-$5.24M-$33.61M-$52.28M-$72.53M-$42.06M-$21.97M-$13.38M-$8.81M-$6.61M-$4.48M
Investing cash flow-$31.0K-$16.18M$758.0K-$4.74M-$3.72M-$55.0K-$27.0K-$26.6K-$5.3K-$21.8K
Financing cash flow$5.59M$31.28M$31.17M$38.21M$104.31M$33.01M$11.38M$15.50M$7.56M$4.30M
Share repurchases------$101.1K---
Stock-based compensation$1.71M$6.45M$11.14M$19.53M$15.01M$2.04M$1.57M$1.23M$1.05M$747.4K
Depreciation and amortization$105.0K$1.20M$2.93M$2.46M$226.0K-----

Key ratios

Key ratios
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Revenue growth, YoY-97.6%22.1%550.4%-24.6%------
Net income growth, YoY-99.0%---------
Gross margin-207.0%-61.6%-161.8%-858.6%-17.0%-----
Operating margin-30712.7%-1485.4%-2805.7%-24161.0%-10878.6%-----
Net margin564.8%1328.6%-2617.3%-23602.9%-10069.4%-----
Free cash flow margin-7376.1%-1122.2%-2132.1%-19237.4%-8412.0%-----
Return on equity1.2%---813.8%-63.4%-----
Return on assets1.0%129.8%-193.8%-164.8%-57.9%-173.3%-227.3%-211.5%-580.6%-649.2%
Current ratio0.170.060.451.0710.93-0.550.770.640.62

Source: XBRL data PAVmed Inc. files with the SEC, latest filing dated Aug 13, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures and share counts are restated for stock splits the filings show: 1-for-15, first reported Aug 12, 2024; 1-for-30, first reported Mar 27, 2026.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

PAVM peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
PAVM$112.0K-89.0%-$12.09M-10794.6%$13.0M
LUCD$5.45M+24.9%-$52.26M-959.8%$84.9M
MDT$37.54B+9.8%$5.24B14.0%$131.48B
BSX$21.07B+8.9%$3.50B16.6%$63.81B
TFX$2.26B+20.9%$304.64M13.5%$6.14B
BDX$23.25B+17.4%$941.00M4.0%$58.63B
SYK$26.30B+7.9%$3.62B13.8%$124.00B

PAVM FAQ

8 questions
  • What is PAVM revenue?
    PAVmed Inc. (PAVM) reported $112.0K of revenue for the twelve months ended Jun 30, 2026. That is down 89.0% from the year before. Revenue for fiscal 2025 was $71.0K.
  • Is PAVM profitable?
    No. PAVmed Inc. reported a net loss of $12.09M for the twelve months ended Jun 30, 2026.
  • How much cash and debt does PAVM have?
    PAVmed Inc. reported $3.78M in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • How fast is PAVM revenue growing?
    PAVmed Inc.'s revenue changed -97.6% in fiscal 2025, to $71.0K.
  • What is PAVM gross margin?
    PAVmed Inc.'s gross profit was -$247.0K on $112.0K of revenue for the twelve months ended Jun 30, 2026, a gross margin of -220.5%.
  • What is PAVM free cash flow?
    PAVmed Inc. generated -$7.78M of free cash flow for the twelve months ended Jun 30, 2026, which is operating cash flow of -$7.73M less capital expenditures.
  • When did PAVM last report financial results?
    The latest statements here come from PAVmed Inc.'s 10-Q filed on Aug 13, 2026, covering the period ended Jun 30, 2026.
  • Where does this PAVM financial data come from?
    Quantisnow builds these statements from the structured XBRL data PAVmed Inc. files with the SEC. It is provided for information only and is not investment advice.